Drug Price Trends for DRIZALMA

Average Pharmacy Cost for DRIZALMA

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
DRIZALMA SPRINKLE DR 20 MG CAP	47335-0616-30	7.17188	EACH	2026-04-01
DRIZALMA SPRINKLE DR 30 MG CAP	47335-0617-30	7.21864	EACH	2026-04-01
DRIZALMA SPRINKLE DR 60 MG CAP	47335-0619-30	7.15708	EACH	2026-04-01
DRIZALMA SPRINKLE DR 20 MG CAP	47335-0616-30	7.14344	EACH	2026-03-18

Drizalma (delgocitinib) Market Analysis and Price Projections: Revenue Outlook, Pricing Benchmarks, and Generic/Biosimilar Risk

Last updated: July 24, 2026

Drizalma’s market outlook and price path depend on its FDA-approved indication scope, dosing strength(s), label restrictions, payer access, and the timing of exclusivity and patent/Paragraph IV challenges. This briefing cannot be completed to required standards because the drug name “DRIZALMA” does not uniquely resolve to a specific FDA-approved product with verifiable label, strength, dosing regimen, launch timeline, and Orange Book exclusivity/patent data in the information available in this session.

What is Drizalma and what are the FDA-approved indications that drive uptake and pricing?
Featured answer: Drizalma’s pricing and commercial ceiling are primarily determined by its approved indication(s), dosing frequency, and whether it targets a chronic or episodic treatment population.

• Key commercial drivers that determine pricing power

  • Label scope: severity (mild/moderate/severe), comorbid populations, pediatric restrictions
  • Site of care: outpatient vs specialty clinic vs self-administered at home
  • Comparative claims: monotherapy vs add-on, endpoints tied to guideline positioning
  • Safety/tolerability profile: dosing persistence and step-therapy impact

• Data needed to model price and volume (not available here)

  • Exact FDA label(s) and dosing instructions
  • Launch date(s) and initial commercial forecast references
  • Treatment population size and addressable segments

When will Drizalma face exclusivity and patent expiry that reshape pricing?
Featured answer: The first meaningful price compression typically arrives at the earlier of (1) end of regulatory exclusivity (data exclusivity or pediatric exclusivity), (2) patent expiration for key Orange Book-listed claims, or (3) first generic/authorized entrant entry post-challenge.

• Exclusivity and patent “cliffs” that move net price

  • 5-year New Chemical Entity (NCE) exclusivity (if applicable)
  • 3-year New Clinical Investigation or related exclusivity (if applicable)
  • Pediatric exclusivity extension (6 months) if applicable
  • Patent expiration schedule for formulation, method-of-use, and manufacturing claims
  • Settlement agreements that delay entry

• Data needed to build a timeline (not available here)

  • Orange Book listing dates and exclusivity determinations
  • Patent numbers, claims, assignees, and estimated expiration/adjusted dates

How many patents cover Drizalma and what is the patent estate strength versus generics?
Featured answer: Estate strength is measured by the number of Orange Book-listed patents, their claim scope (method-of-use vs formulation vs process), and whether remaining patents are likely to block FDA approval of competing applications.

• Patent estate features that affect generic timing

  • Multiple independent method-of-use claims can delay skinny labeling substitutes
  • Formulation/process patents can force manufacturing redesign or price/market leverage disputes
  • Narrow patents may be designed around; broad ones drive settlement pressure

• Data needed to quantify patent estate (not available here)

  • Orange Book: patent count, status (expired/active), and listed dosage forms/strengths
  • Litigation/Paragraph IV track record by applicant family

What generic entry risks exist for Drizalma and how would they change net pricing?
Featured answer: Generic entry risk depends on whether Paragraph IV challenges are filed, whether an FDA “suitability” bottleneck exists, and whether authorized generics are used as a pricing lever.

• Entry channels that move price

  • First Paragraph IV generic: often triggers steep net price cuts even before full class volume capture
  • Authorized generic: can blunt price erosion pace but limits long-term upside
  • Launch-to-switch time: payer criteria and prior authorization requirements determine switching speed

• Data needed to model entry scenarios (not available here)

  • Any filed ANDAs/authorized generics tied to Drizalma
  • Litigation dockets and settlement timing for forecast constraints

What is the Orange Book status of Drizalma (patents, exclusivity, and listed dosage forms)?
Featured answer: Orange Book status determines the lawful “barrier” to generic substitution and informs the end date for exclusivity-linked price protection.

• Required Orange Book elements to project pricing

  • Granted patents with expiration dates
  • FDA exclusivity end dates by exclusivity type
  • Listed proprietary drug products by dosage form/strength

• Data not available in-session to produce a compliant table

  • Orange Book listing identifiers and expiration schedule

How does Drizalma compare with competing therapies on dosing, outcomes, and payer positioning?
Featured answer: A higher net price can persist if Drizalma has demonstrable clinical differentiation that reduces total cost of care or improves adherence.

• Benchmarking framework for price projection

  • Dosing frequency and duration-of-therapy assumptions
  • Clinical outcomes relative to incumbents and standard of care
  • Evidence strength tied to endpoints payers use for coverage
  • Formulary access patterns (preferred tier, step edits)

• Data needed to complete comparison table (not available here)

  • Competitor list, labeled indications, and dosing regimens
  • Comparative effectiveness outcomes and payer use restrictions

What formulations are protected by Drizalma patents and what manufacturing/IP barriers exist?
Featured answer: Formulation and process patents determine whether would-be entrants can produce a therapeutically equivalent product without design-around.

• Typical patent-to-manufacturing implications

  • Specific excipient systems and particle/solubility parameters affect BE and formulation replication
  • Process steps can raise cost and create “scope” leverage in litigation
  • Device/delivery system patents can block switches even when active ingredient is generic

• Data needed to map formulation/IP coverage (not available here)

  • Claims-by-formulation from Orange Book and corresponding patent specifications

What patent litigation affects Drizalma and how do settlements affect launch calendars?
Featured answer: Litigation outcomes and settlements control whether generic entry occurs at patent expiry, earlier by design-around, or later by agreed launch dates.

• Litigation inputs required for a forecast-quality model

  • Filed Paragraph IV suits and court dockets
  • Claim construction outcomes and injunction history
  • Final settlement dates and “no launch” periods

• Data not available in-session to report legally relevant dates

  • Any Drizalma-specific litigation or settlement terms

How is Drizalma priced today (WAC/ASP) and what net price discounts should be modeled?
Featured answer: Net price is the binding variable for revenue forecasts, driven by rebates, discounts, and wholesaler and channel terms.

• Price inputs to project revenue accurately

  • WAC and any publicly disclosed launch pricing
  • ASP/AMP history by quarter after launch
  • Contracting: 340B, Medicaid FSS, Medicare Part D negotiated discounts
  • Specialty pharmacy channel economics if relevant

• Data not available in-session to produce WAC/ASP baseline and discount curves

What price projections for Drizalma are implied by exclusivity duration, uptake curve, and payer pressure?
Featured answer: Price declines typically start before exclusivity ends if payer leverage increases, if competitors launch, or if coverage criteria tighten.

• Projection structure for business planning

  • Year 1 to Year 3: “launch premium” vs formulary attainment and utilization management
  • Year 4 to Year 6: erosion from competitive pipeline and internal payer cost controls
  • Post-exclusivity: generic/authorized entry triggers step-change net price reductions

• Data missing to produce numeric projections

  • Baseline price, dosing, patient mix, coverage rates, and competitor timing

Key tables that should be produced for an investable Drizalma pricing model (not available here)

Table 1. Required Drizalma pricing inputs for projection
| Variable | What it drives | Needed source | |---|---|---| | Launch WAC by strength | Gross revenue ceiling | Product label / pricing database | | ASP by quarter | Net price trend validation | CMS ASP/AMP | | Rebates/discount range | Net revenue accuracy | payer contract assumptions | | Dosing duration | Units per patient | FDA label | | Average treated patients by year | Volume ramp | forecast model |

Table 2. Required exclusivity and patent timeline
| Barrier | Date type | Needed fields | |---|---|---| | Regulatory exclusivity end | date | exclusivity type and end date | | Key Orange Book patents | expiration | patent numbers and adjusted dates | | Litigation/settlement | gating | entry dates and injunction outcomes |

Table 3. Generic entry scenarios that move net price
| Scenario | Entry timing | Net price impact driver | |---|---|---| | No challenge, delayed entry | at expiry | standard erosion curve | | Early Paragraph IV entry | before expiry | immediate shelf disruption | | Authorized generic | timed with/or before generics | mitigates price shock |

Key Takeaways

• A defensible market analysis and price projection for Drizalma requires verified FDA label details, Orange Book listings (patents and exclusivity), and current pricing/ASP inputs.
• This session does not contain the underlying verifiable identifiers needed to generate the required revenue, pricing, exclusivity, and entry-calendar tables.

FAQs

1. What determines Drizalma net price more: rebates, payer mix, or dosing-driven units?
2. How do Orange Book method-of-use patents versus formulation patents change generic switch timing?
3. What is the typical net price erosion curve after first generic entry for specialty drugs?
4. How do settlement “no-launch” dates translate into revenue protection periods?
5. Which FDA regulatory events (supplements, labeling expansions) most often extend or shrink pricing power?

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-07-24).
2. CMS Drug Pricing Data (ASP/AMP). (Accessed 2026-07-24).